Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL

Both CAR-Ts Offer Survival Gains, With Longer Data For Kite’s Product

 
• By Mandy Jackson
  
Game changer as a business creative metaphor art
After years with chemo and stem cell transplant as the only second-line option, CAR-T therapy offers a more effective solution • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D